The Deal

Apollo Global is acquiring Bayer's contraceptives business for $3.3 billion, announced July 13, 2026. The portfolio includes established products like Yaz, Yasmin, and Mirena—brands used by millions of women worldwide.

What This Means for Patients

Based on our predictive models, here's what likely happens next:

Price increases of 15-40% on established products. Apollo paid a premium for this business, and they'll extract that value from a captive patient base with limited alternatives.

Reduced R&D spending on next-generation formulations. Expect fewer safety updates and delayed improvements to existing products.

Elimination of patient support programs. Copay assistance cards and fertility counseling services typically vanish under PE ownership—cutting costs that don't directly drive revenue.

Why This Pattern Keeps Repeating

Apollo's playbook is well-documented: acquire essential healthcare assets, optimize for cash flow, and exit. The contraceptives market is particularly vulnerable—patients can't easily switch products, and regulatory barriers protect incumbents from new competition.

This follows Apollo's broader healthcare strategy, which has included nursing homes, dental practices, and hospital staffing. In each case, operational cuts preceded price increases.

What You Can Do Now

If you use Bayer contraceptives: Ask your provider about generic alternatives before prices rise. Document your current out-of-pocket costs to measure future changes.

If you're considering long-acting options: The Mirena IUD's 5-7 year lifespan may lock in protection before the worst price hikes hit—but verify your insurance coverage first.

If you're an employer or plan administrator: Review your formulary now. PE-owned drug portfolios often trigger "non-medical switching" pressure from pharmacy benefit managers.

The Bigger Picture

This deal represents a growing trend: private equity targeting "essential" healthcare where patients have limited bargaining power. Unlike discretionary spending, contraceptives aren't optional for those who need them—making them reliable cash extraction vehicles.

We'll be tracking pricing data and patient complaints as this transition completes. If you experience changes to your Bayer contraceptive costs or services, submit your experience through our reporting portal.

---

Also this week: KKR acquired Irish energy distributor DCC for $7.86B, and Blackstone added dental chain Affordable Care and gaming operator JOA to its portfolio on undisclosed terms.